Oculis (OCS): Privosergtor’s Breakthrough Profile in Optic Neuritis Supports First-in-Class Upside and Buy Rating
I'm PortAI, I can summarize articles.
LifeSci Capital analyst Patrick Dolezal has maintained a Buy rating on Oculis (OCS) stock, citing the strong clinical and regulatory profile of privosergtor in optic neuritis. The FDA’s Breakthrough Therapy Designation highlights the drug's potential to outperform current treatments, supported by promising Phase 2 ACUITY data. The launch of the pivotal PIONEER-1 trial marks a transition to late-stage development. Dolezal believes privosergtor could achieve significant commercial success, similar to Tepezza in thyroid eye disease. H.C. Wainwright also reiterated a Buy rating with a $42.00 price target.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments